DTech Liquidating

DTech Liquidating Receivables

Delisted

The Accounts Receivable of DTech Liquidating (DMTKQ) as of Nov 21, 2026 is 2.58 M USD. In the previous year, Accounts Receivable was 4.20 M USD — a change of -38.48% (lower).

Receivables

2.58 MUSD

YoY

-38.48%

Last updated:

Accounts Receivable of DTech Liquidating is 2023 2.58 M USD. Accounts Receivable of DTech Liquidating was 2022 4.20 M USD. It decreases by -38.48% lower compared to the previous year.

The DTech Liquidating Receivables history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Receivables
Date
Receivables
Jan 1, 2019
700,000.00 USD
Jan 1, 2020
1.50 M USD
Jan 1, 2021
3.80 M USD
Jan 1, 2022
4.20 M USD
Jan 1, 2023
2.58 M USD
The DTech Liquidating Receivables history
YEARReceivablesYoY
2.58 MUSD-38.48%
4.20 MUSD+10.53%
3.80 MUSD+153.33%
1.50 MUSD+114.29%
700,000.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

DTech Liquidating Stock analysis

What does DTech Liquidating do? DermTech, Inc. develops and sells non-invasive genomics tests for skin disease diagnosis and treatment, focusing on melanoma detection. The company's primary product, the DermTech Melanoma Test (DMT), marketed as Pigmented Lesion Assay (PLA), analyzes skin samples collected via Smart Stickers to identify genomic markers linked to melanoma. Healthcare providers and dermatologists purchase these tests to assess pigmented skin lesions, addressing unmet needs in diagnosing melanoma early. The company's technology enables non-invasive early detection of higher-risk lesions, reducing unnecessary biopsies. DermTech's commercial test targets the diagnostic pathway for pigmented skin lesions, commonly known as moles, which are dark-colored patches of skin. The firm's focus on inflammatory skin diseases and aging-related skin conditions complements its melanoma detection offerings. By enhancing early melanoma detection through genomic analysis, DermTech provides a solution for clinicians managing skin cancer risks without invasive procedures. The company's products are designed to facilitate clinical assessment of skin lesions that raise melanoma concerns, streamlining the diagnostic process. DermTech's approach to non-invasive testing supports healthcare systems by improving efficiency in skin cancer management. The firm's technology specifically addresses genomic markers associated with melanoma, offering a targeted solution for high-risk lesion identification. DTech Liquidating is one of the most popular companies on Eulerpool.

Frequently Asked Questions about DTech Liquidating stock

Accounts Receivable of DTech Liquidating is 2.58 M USD in 2023.

Accounts Receivable of DTech Liquidating changed from 4.20 M USD to 2.58 M USD, representing a -38.48% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Accounts Receivable DTech Liquidating since 2006 – with annual values, charts, and detailed analysis.

Receivables represent money owed to the company by customers for goods or services delivered. High receivables relative to revenue may indicate collection issues.

Accounts Receivable's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Accounts Receivable's DTech Liquidating historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — DTech Liquidating

All Key Metrics — DTech Liquidating